Q-omics provides the consensus-scored TBL1X profile across patient tissues and cancer cell-line models. TBL1X expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBL1X is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TBL1X RNA expression shows 19,762 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TBL1X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBL1X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBL1X survival associations across molecular data types. TBL1X RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBL1X RNA expression–survival associations across cancer types. High TBL1X expression shows unfavorable associations in LIHC, ACC and COAD, but favorable associations in KIRC, PAAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBL1X RNA expression.
This table summarizes TBL1X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBL1X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBL1X shows lower tumor expression in THCA, BLCA and KICH and higher tumor expression in LUSC, LUAD and LIHC. The THCA box plot shows higher TBL1X RNA expression in normal versus tumor tissue (log2 FC = −1.265, t-test p < 0.001).
This table shows molecular features associated with TBL1X in patient tissues and cancer cell lines. In patient samples, TBL1X shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBL1X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
